Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In our study, 75 patients aged 18-80 years, classified as ASA I-II risk groups, who underwent intracranial surgery performed by the Department of Neurosurgery at Trakya University Faculty of Medicine Hospital, were included. After the patients were positioned on the neurosurgical operating table, heart rate, systolic blood pressure, diastolic blood pressure, peripheral oxygen saturation, and entropy values were measured in all cases. Baseline values were recorded for patients who underwent ANI (Analgesia Nociception Index) monitoring. In both groups, entropy values were targeted to remain within the range of 40-60. In the ANI group, ANI values were maintained between 50-70.
Patients were divided into two groups based on the intraoperative monitoring method applied: the ANI group (n=38) and the control group (n=37). All patients underwent entropy monitoring, while ANI monitoring was exclusively used in the ANI group for pain management. In the ANI group, remifentanil infusion adjustments were made to keep ANI values within the 50-70 range.
This study aimed to compare perioperative opioid consumption, postoperative pain, and recovery from anesthesia in patients undergoing intracranial surgery who received general anesthesia and analgesia management guided by either entropy monitoring alone or a combination of entropy and ANI monitoring.
In this study, we aimed to compare perioperative opioid consumption, postoperative pain, and recovery from anesthesia in patients undergoing intracranial surgery who were managed with general anesthesia and analgesia based on entropy monitoring or a combination of entropy and ANI monitoring during the intraoperative period.
A total of 75 patients aged between 18 and 80 years, classified as ASA I-II, who underwent intracranial surgery at Trakya University Medical Faculty Hospital between January 1, 2021, and January 1, 2024, were included in the study. Patients were divided into two groups based on the intraoperative monitoring techniques used: the ANI group (n=38) and the Control group (n=37). All patients underwent entropy monitoring during the operation. In the ANI group, ANI monitoring was additionally used for pain management.
The study recorded intraoperative data such as mean arterial pressure, heart rate, SpO2, end-tidal CO2, ANI, RE, SE values at baseline, induction, intubation, pin placement, skin incision, craniotomy, dura opening, bleeding control, pin removal, skin closure, and postoperatively. These values were measured at intervals of 5 minutes for the first 20 minutes, then every 10 minutes until 60 minutes, and every 30 minutes up to 180 minutes. Surgical type, anesthesia duration, the amount of erythrocyte suspension and fresh frozen plasma used based on intraoperative requirements, and anesthetic drugs (propofol, rocuronium, fentanyl) were recorded. The total remifentanil consumption was documented via the infusion pump.
Postoperative recovery in the recovery unit was evaluated using the Glasgow Coma Scale (GCS), the Ramsey Sedation Scale, and the duration with a Modified Aldrete Score (MAS) greater than 9. Pain was assessed using the Visual Analog Scale (VAS). VAS values were recorded at 1, 2, 4, 6, 12, and 24 hours. If VAS scores exceeded 4, intravenous paracetamol, tramadol, and meperidine were administered in stepwise treatment. The time to first analgesic use, postoperative analgesic consumption in the first 24 hours, and any postoperative complications were recorded.
Categorical variables were expressed as frequency distributions (number, percentage), and numerical variables were analyzed with descriptive statistics (mean, standard deviation). Differences between the two groups for categorical variables were examined using the independent samples t-test, Pearson correlation analysis was used to assess relationships between two numerical variables, and the Chi-square test was used to analyze relationships between two categorical variables. A p-value of <0.05 was considered statistically significant.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ANI GROUP | ANI MONITORING |
| |
| CONTROL GROUP | STANDARD MONITORING |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ANALGESIA NOCICEPTION INDEX MONITORING | Device | INTRACRANIAL SURGERY |
|
| Measure | Description | Time Frame |
|---|---|---|
| INTRAOPERATIVE OPIOID USE | Lower dose opioid use during surgery is associated with more favorable outcomes in terms of postoperative pain and recovery scores. | during the surgery/procedure |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Seventy-five patients in ASA I-II risk group aged 18-80 who will undergo intracranial surgery by Brain and Nerve Surgery at Trakya University Faculty of Medicine Hospital will be included in the study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| SEVTAP HEKİMOĞLU ŞAHİN | Trakya University | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Trakya Üniversitesi Tip Fakültesi | Edirne | Merkez | 22100 | Turkey (Türkiye) |
Not provided
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D000377 | Agnosia |
| D015192 | Infratentorial Neoplasms |
| D010911 | Pituitary Neoplasms |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
Not provided
Not provided
Not provided
Not provided
Not provided
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009422 | Nervous System Diseases |
| D001932 | Brain Neoplasms |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D004701 | Endocrine Gland Neoplasms |
| D007029 | Hypothalamic Neoplasms |
| D015173 | Supratentorial Neoplasms |
| D007027 | Hypothalamic Diseases |
| D010900 | Pituitary Diseases |
| D004700 | Endocrine System Diseases |